drugset / Trial / NCT07728019
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Phase 2
Recruiting
60 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Jiangsu HengRui Medicine Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
Timeline
- Start
- 2026-07-30
- Primary completion
- 2029-06-30
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 1800 mg | Intravenous |